MX361741B - Tratamientos médicos a base de anamorelina. - Google Patents

Tratamientos médicos a base de anamorelina.

Info

Publication number
MX361741B
MX361741B MX2017002825A MX2017002825A MX361741B MX 361741 B MX361741 B MX 361741B MX 2017002825 A MX2017002825 A MX 2017002825A MX 2017002825 A MX2017002825 A MX 2017002825A MX 361741 B MX361741 B MX 361741B
Authority
MX
Mexico
Prior art keywords
anamorelin
therapeutically effective
medical treatments
treatments based
patient
Prior art date
Application number
MX2017002825A
Other languages
English (en)
Other versions
MX2017002825A (es
Inventor
Lu Ming
Mann William
Friend John
Polvino William
Allen Suzan
Duus Elizabeth
Giorgino Ruben
Baroni Enrico
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX361741(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MX2017002825A publication Critical patent/MX2017002825A/es
Publication of MX361741B publication Critical patent/MX361741B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos de tratamiento de afecciones relacionadas con el cáncer usando anamorelina. La modalidad principal se relaciona con la afección única de pacientes que la definen mediante el tratamiento de la caquexia en un paciente humano con cáncer, que comprende la administración a dicho paciente de una cantidad terapéuticamente efectiva de anamorelina durante un período terapéuticamente efectivo, y la sorprendente capacidad observada de la anamorelina de aumentar la masa corporal magra de esta población.
MX2017002825A 2014-09-04 2015-08-28 Tratamientos médicos a base de anamorelina. MX361741B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (2)

Publication Number Publication Date
MX2017002825A MX2017002825A (es) 2017-09-28
MX361741B true MX361741B (es) 2018-12-14

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002825A MX361741B (es) 2014-09-04 2015-08-28 Tratamientos médicos a base de anamorelina.

Country Status (44)

Country Link
US (5) US9675600B2 (es)
EP (2) EP3188599B1 (es)
JP (3) JP6356907B2 (es)
KR (3) KR102307275B1 (es)
CN (5) CN113577074A (es)
AP (1) AP2017009772A0 (es)
AR (1) AR103118A1 (es)
AU (1) AU2015312231B2 (es)
BR (1) BR112017003552A2 (es)
CA (1) CA2959158A1 (es)
CL (1) CL2017000494A1 (es)
CO (1) CO2017003263A2 (es)
CR (1) CR20170121A (es)
CY (1) CY1122746T1 (es)
DK (1) DK3188599T3 (es)
DO (1) DOP2017000055A (es)
EA (1) EA035578B1 (es)
EC (1) ECSP17019893A (es)
ES (1) ES2761777T3 (es)
GE (1) GEP20186939B (es)
HR (1) HRP20192345T1 (es)
HU (1) HUE046894T2 (es)
IL (1) IL250692B (es)
JO (1) JO3541B1 (es)
LT (1) LT3188599T (es)
MA (1) MA40607B1 (es)
MD (1) MD4710C1 (es)
ME (1) ME03597B (es)
MX (1) MX361741B (es)
MY (1) MY187167A (es)
NI (1) NI201700024A (es)
PE (1) PE20171109A1 (es)
PH (1) PH12017500392B1 (es)
PL (1) PL3188599T3 (es)
PT (1) PT3188599T (es)
RS (1) RS59751B1 (es)
SG (1) SG11201701567UA (es)
SI (1) SI3188599T1 (es)
SV (1) SV2017005400A (es)
TN (1) TN2017000040A1 (es)
TW (1) TWI639429B (es)
UA (1) UA120765C2 (es)
UY (1) UY36286A (es)
WO (1) WO2016036598A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
JP6356907B2 (ja) 2014-09-04 2018-07-11 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
JP2022546162A (ja) 2019-08-30 2022-11-04 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法
EP4049658A4 (en) * 2019-10-24 2023-11-22 Toray Industries, Inc. THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST CACHEXIA
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
US20050261201A1 (en) 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
WO2008100448A2 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
WO2013175805A1 (en) 2012-05-25 2013-11-28 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria
JP6356907B2 (ja) 2014-09-04 2018-07-11 ヘルシン ヘルスケア ソシエテ アノニム アナモレリンに基づく医療

Also Published As

Publication number Publication date
RS59751B1 (sr) 2020-02-28
AP2017009772A0 (en) 2017-02-28
KR20180085047A (ko) 2018-07-25
PE20171109A1 (es) 2017-08-07
CN107205389A (zh) 2017-09-26
PT3188599T (pt) 2020-01-15
BR112017003552A2 (pt) 2017-12-05
AR103118A1 (es) 2017-04-19
US20170296526A1 (en) 2017-10-19
MA40607B1 (fr) 2019-11-29
EP3590338A3 (en) 2020-03-18
CN113577074A (zh) 2021-11-02
EP3188599A1 (en) 2017-07-12
PL3188599T3 (pl) 2020-06-01
UY36286A (es) 2016-02-29
IL250692A0 (en) 2017-04-30
HUE046894T2 (hu) 2020-04-28
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
JO3541B1 (ar) 2020-07-05
US11723902B2 (en) 2023-08-15
DOP2017000055A (es) 2017-08-15
US10278964B2 (en) 2019-05-07
MD4710B1 (ro) 2020-09-30
CA2959158A1 (en) 2016-03-10
US9675600B2 (en) 2017-06-13
KR20210035923A (ko) 2021-04-01
PH12017500392A1 (en) 2017-07-17
CN109172575A (zh) 2019-01-11
EP3188599A4 (en) 2017-10-11
US20160067236A1 (en) 2016-03-10
PH12017500392B1 (en) 2017-07-17
JP2017526695A (ja) 2017-09-14
MD20170025A2 (ro) 2017-07-31
KR20170047372A (ko) 2017-05-04
HRP20192345T1 (hr) 2020-03-20
SG11201701567UA (en) 2017-03-30
CR20170121A (es) 2017-07-17
KR102234319B1 (ko) 2021-04-01
JP6923486B2 (ja) 2021-08-18
KR101881264B1 (ko) 2018-07-23
NI201700024A (es) 2017-07-18
CN107375285A (zh) 2017-11-24
WO2016036598A1 (en) 2016-03-10
ME03597B (me) 2020-07-20
ES2761777T3 (es) 2020-05-21
LT3188599T (lt) 2019-12-10
ECSP17019893A (es) 2017-05-31
EP3188599B1 (en) 2019-10-02
CL2017000494A1 (es) 2017-09-15
MY187167A (en) 2021-09-07
CY1122746T1 (el) 2021-03-12
US20190175574A1 (en) 2019-06-13
JP7044918B2 (ja) 2022-03-30
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
UA120765C2 (uk) 2020-02-10
CN113577073A (zh) 2021-11-02
TW201613587A (en) 2016-04-16
MX2017002825A (es) 2017-09-28
AU2015312231A1 (en) 2017-03-23
US20240024303A1 (en) 2024-01-25
SV2017005400A (es) 2017-04-20
AU2015312231B2 (en) 2017-10-19
JP2018154655A (ja) 2018-10-04
TWI639429B (zh) 2018-11-01
NZ729673A (en) 2023-09-29
TN2017000040A1 (en) 2018-07-04
IL250692B (en) 2019-05-30
JP6356907B2 (ja) 2018-07-11
EP3590338A2 (en) 2020-01-08
SI3188599T1 (sl) 2020-02-28
US10894041B2 (en) 2021-01-19
KR102307275B1 (ko) 2021-09-30
MD4710C1 (ro) 2021-04-30
CO2017003263A2 (es) 2017-07-28
US20210093627A1 (en) 2021-04-01
JP2021080281A (ja) 2021-05-27

Similar Documents

Publication Publication Date Title
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2019003751A (es) Proteina terapeutica.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
UA113183C2 (xx) Спосіб лікування адикції

Legal Events

Date Code Title Description
FG Grant or registration